• AMGN

Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug

Amgen shares rose after confirming no bone density issues with its MariTide obesity treatment, despite previous concerns. Focus shifts to upcoming Phase 2 trial results.

• AMGN
• ESZ24
• META
• MSFT
• NQZ24
• RIVN
• SAVE
• TSLA
• US10YT=X

Futures slip as markets await inflation data for clues on Fed's rate path

U.S. stock index futures fall ahead of inflation data, with mixed results in major stocks and concerns over Treasury yields and potential interest rate cuts.

• AMGN

Amgen dismisses bone density concerns related to its new weight-loss drug

Amgen reassured that its weight-loss drug MariTide poses no bone density risks after concerns significantly impacted its stock value, with analysts deeming the worries exaggerated.

• AMGN
• AMZN
• CL
• DJI
• DOW
• DX
• DXCM
• EUR/USD
• GC
• HON
• INTC
• IXIC
• LCO
• LYV
• MOS
• MSFT
• TSN
• US500
• USD/JPY
• VIX

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.86%

• AMGN
• CL
• DIS
• DJI
• EUR/USD
• GC
• IXIC
• LCO
• US500
• USD/JPY
• VIX
• VZ

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.90%

U.S. stocks fell on Thursday, led by declines in technology and materials, with notable losses from major firms including Microsoft and Estee Lauder.

• AMGN

Earnings call: Amgen reports robust Q3 growth with $8.5 billion in revenue

Amgen's Q3 2024 results show robust revenue growth of 23% driven by strong product performance and advancements in innovative treatments for obesity, diabetes, and cancers.

• AMGN

Amgen beats Q3 earnings estimates, raises full-year guidance

Amgen reported Q3 earnings exceeding expectations, with strong sales growth and raised guidance for 2024, highlighting a strategic focus on product portfolio and market momentum.

• AMGN

Amgen earnings beat by $0.47, revenue fell short of estimates

Amgen's Q3 EPS of $5.58 exceeded estimates; revenue was slightly below. FY 2024 EPS guidance is $19.20-$20.00, with financial health rated as good.

• AMGN

Amgen posts higher profit, obesity data on track for late this year

Amgen's quarterly profit rose due to increased drug sales, with a focus on upcoming obesity medicine trial results, while adjusting financial outlook for the year.

• AMGN
• AZN
• CTLT
• NVO
• PFE
• RHHBY

Roche comes out against allowing takeover of drug manufacturer Catalent

Roche's CEO urged authorities to block Novo Nordisk's acquisition of Catalent, citing potential competition issues in the weight-loss drug market, raising concerns for smaller competitors.